Lymphocytopenia repercussions on stage III Non-small cell lung cancer (NSCLC) patients\' tumour progression and their clinical results after chemoradiation

According to earlier research, tumour response, Lymphocytopenia, and a system-wide immune-inflammatory indexes all affect the clinical results of Stage III NSCLC. We postulated that the tumour response to CRT would be related to hematologic parameters and could perhaps anticipate clinical results.Retrospective evaluation of stage III NSCLC patients treated at a single facility between 2015 and 2020 was done. After receiving CRT, the pre-treatment gross tumour volume (GTV) was measured again. Full blood counts were taken before, during, and after treatment. Neutrophil platelet lymphocyte was used to define the systemic immune-inflammation index (SII). Kaplan-Meier estimates were used to compute overall survival (OS) and prognosis-free survival (PFS), which were then compared using Wilcoxon tests. Then, taking into account additional baseline parameters, pseudovalue regression was used to provide a multivariate study of hematopoietic factors affecting controlled average duration.There were 110 patients in total. The median PFS and OS were 20 and 35 months, respectively, after a median follow-up of 24 months. Baseline SII was correlated with OS (p = 0.039) but not PFS (p = 0.10), and baseline ALC was correlated with both PFS and OS (p = 0.13 and p = 0.06, respectively) in the multivariate model. The recovery SII, nadir ALC, and nadir SII were not connected to PFS or OS.: Baseline hematologic variables, such as baseline ALC, baseline SII, and recovery ALC, were related to clinical outcomes in this cohort of patients with stage III NSCLC. The relationship between disease response and hematologic variables or clinical outcomes was not strong.